SUVENPHAR

Suven Pharmaceuticals Share PriceSuven Pharmaceuticals

₹468.6
-1.7 (-0.36%)
As on 22 March, 2023 | 02:44 BSE: 543064 NSE: SUVENPHAR

Suven Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Suven Pharmaceuticals

Start SIP

Suven Pharmaceuticals Share Price

  • Over 1 Month -2.65%
  • Over 3 Month -3.6%
  • Over 6 Month 1.83%
  • Over 1 Year -10.2%

Suven Pharmaceuticals Key Statistics

P/E Ratio 31.5
PEG Ratio -2.1
Market Cap Cr 11,929
Price to Book Ratio 7.8
EPS 21.4
Dividend 1.7
Relative Strength Index 35.09
Money Flow Index 19.58
MACD Signal -3.16
Average True Range 6.53

Suven Pharmaceuticals Investment Rating

  • Master Rating:
  • Suven Pharmaceuticals has an operating revenue of Rs. 1,334.82 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 47% is great, ROE of 29% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 56 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Financials
IndicatorDec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 348278339364
Operating Expenses Qtr Cr 201172184206
Operating Profit Qtr Cr 147107155158
Depreciation Qtr Cr 11111110
Interest Qtr Cr 1012
Tax Qtr Cr 38274055
Net Profit Qtr Cr 10979114224

Suven Pharmaceuticals Technicals

EMA & SMA

Current Price
₹468.6
-1.7 (-0.36%)
  • Bullish Moving Average
  • ___
  • 2
  • Bearish Moving Average
  • ___
  • 14
  • 20 Day
  • 476.32
  • 50 Day
  • 479.09
  • 100 Day
  • 476.3
  • 200 Day
  • 477.68
  • 20 Day
  • 476.35
  • 50 Day
  • 484.77
  • 100 Day
  • 473.85
  • 200 Day
  • 464.8

Suven Pharmaceuticals Resistance and Support

PIVOT
₹471.42
Resistance
First Resistance 475.54
Second Resistance 480.77
Third Resistance 484.89
RSI 35.1
MFI 19.58
MACD Single Line -3.16
MACD -3.64
Support
First Resistance 466.19
Second Resistance 462.07
Third Resistance 456.84

Suven Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 234,555 19,116,233 81.5
Week 175,169 14,898,157 85.05
1 Month 190,293 15,638,259 82.18
6 Month 344,602 21,678,884 62.91

Suven Pharmaceuticals Result Highlights

Suven Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1320.22 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2022. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.
Market Cap 11,942
Sales 1,330
Shares in Float 10.18
No of funds 154
Yield 0.64
Book Value 7.84
U/D Vol ratio 0.9
LTDebt / Equity 2
Alpha -0.02
Beta 0.4

Suven Pharmaceuticals

Owner NameDec-22Sep-22Jun-22Mar-22
Promoters 60%60%60%
Mutual Funds 8.97%8.28%6.32%
Insurance Companies 2.23%2.24%
Foreign Portfolio Investors 8.11%7.58%8.49%
Financial Institutions/ Banks
Individual Investors 14.01%14.69%16.86%
Others 6.68%7.21%8.33%

Suven Pharmaceuticals Management

Name Designation
Mr. Venkateswarlu Jasti Managing Director
Ms. Deepanwita Chattopadhyay Independent Director
Dr. Jerry Jeyasingh Non Exe.Non Ind.Director
Mr. J V Ramudu Chairman, Non Ind & Non Exe Director
Mr. D G Prasad Independent Director
Dr. V Sambasiva Rao Independent Director

Suven Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Suven Pharmaceuticals MF Shareholding

Name Amount(cr)
UTI Flexi Cap Fund Regular Plan Growth 23945
HSBC Small Cap Fund Fund Regular Growth 8672
HSBC Midcap Fund Growth 7089
UTI Value Opportunities Fund Regular Plan Growth 6741
PGIM India Flexi Cap Fund Regular Growth 5199

Suven Pharmaceuticals FAQs

What is Share Price of Suven Pharmaceuticals ?

Suven Pharmaceuticals share price is ₹468 As on 22 March, 2023 | 02:30

What is the Market Cap of Suven Pharmaceuticals ?

The Market Cap of Suven Pharmaceuticals is ₹11928.9 Cr As on 22 March, 2023 | 02:30

What is the P/E ratio of Suven Pharmaceuticals ?

The P/E ratio of Suven Pharmaceuticals is 31.5 As on 22 March, 2023 | 02:30

What is the PB ratio of Suven Pharmaceuticals ?

The PB ratio of Suven Pharmaceuticals is 7.8 As on 22 March, 2023 | 02:30

Q2FY23

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number